Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025
Artiva Biotherapeutics (NASDAQ:ARTV), a clinical-stage biotech company focused on cell therapies for autoimmune diseases and cancers, will participate in the Cantor Global Healthcare Conference 2025. The company's management will engage in a fireside chat on September 3, 2025, at 9:45 a.m. EDT.
The presentation will be accessible through a live webcast in the "Investors" section of Artivabio.com, with the replay available for 90 days after the event. Management will also be available for meetings with registered conference attendees.
Artiva Biotherapeutics (NASDAQ:ARTV), azienda biotech in fase clinica specializzata in terapie cellulari per malattie autoimmuni e tumori, parteciperà al Cantor Global Healthcare Conference 2025. Il management terrà un fireside chat il 3 settembre 2025 alle 9:45 AM EDT.
La presentazione sarà trasmessa in diretta via webcast nella sezione "Investors" di Artivabio.com; la registrazione resterà disponibile per 90 giorni dall'evento. Il team dirigenziale sarà inoltre disponibile per incontri con i partecipanti registrati alla conferenza.
Artiva Biotherapeutics (NASDAQ:ARTV), una biotecnológica en fase clínica centrada en terapias celulares para enfermedades autoinmunes y cánceres, participará en la Cantor Global Healthcare Conference 2025. La dirección ofrecerá una charla informativa el 3 de septiembre de 2025 a las 9:45 a.m. EDT.
La presentación se podrá ver en directo mediante webcast en la sección "Investors" de Artivabio.com; la grabación estará disponible durante 90 días tras el evento. La dirección también atenderá reuniones con los asistentes registrados en la conferencia.
Artiva Biotherapeutics (NASDAQ:ARTV)는 자가면역 질환 및 암에 대한 세포치료제 개발에 주력하는 임상 단계 바이오텍으로, Cantor Global Healthcare Conference 2025에 참가합니다. 경영진은 2025년 9월 3일 오전 9:45(EDT)에 파이어사이드 채팅을 진행합니다.
발표는 Artivabio.com의 "Investors" 섹션을 통해 라이브 웹캐스트로 시청할 수 있으며, 행사 후 90일 동안 재생 목록이 제공됩니다. 경영진은 컨퍼런스에 등록한 참석자들과의 미팅도 예정되어 있습니다.
Artiva Biotherapeutics (NASDAQ:ARTV), une société biotechnologique en phase clinique spécialisée dans les thérapies cellulaires pour les maladies auto-immunes et les cancers, participera à la Cantor Global Healthcare Conference 2025. La direction tiendra un fireside chat le 3 septembre 2025 à 9h45 EDT.
La présentation sera diffusée en direct via webcast dans la rubrique « Investors » d'Artivabio.com ; le replay sera disponible pendant 90 jours après l'événement. La direction restera également disponible pour des réunions avec les participants inscrits à la conférence.
Artiva Biotherapeutics (NASDAQ:ARTV), ein Biotech-Unternehmen in der klinischen Entwicklungsphase mit Schwerpunkt auf Zelltherapien für Autoimmunerkrankungen und Krebs, nimmt an der Cantor Global Healthcare Conference 2025 teil. Das Management führt ein Fireside-Chat am 3. September 2025 um 9:45 Uhr EDT.
Die Präsentation wird per Live-Webcast im Bereich "Investors" auf Artivabio.com zugänglich sein; die Aufzeichnung steht 90 Tage nach der Veranstaltung zur Verfügung. Das Management steht zudem für Meetings mit registrierten Konferenzteilnehmern zur Verfügung.
- None.
- None.
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 9:45 a.m. EDT.
Members of the Artiva management team will also be available to participate in investor meetings with investors who are registered to attend the conference.
Investors and the general public are invited to listen to a live webcast of the presentation through the "Investors" section on Artivabio.com. A webcast replay will be made available following the event for 90 days.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases. This includes two company-sponsored trials, a trial in systemic lupus erythematosus for patients with or without lupus nephritis and a basket trial across autoimmune diseases including rheumatoid arthritis and Sjögren’s disease, as well as an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding upcoming events or Artiva Biotherapeutics, Inc.’s (the “Company”) participation at such events. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investors: Neha Krishnamohan, Artiva Biotherapeutics, ir@artivabio.com
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com
Source: Artiva Biotherapeutics, Inc.
